PatchSiren

PatchSiren cyber security CVE debrief

CVE-2023-38950 ZKTeco CVE debrief

CVE-2023-38950 is a path traversal vulnerability affecting ZKTeco BioTime and is listed by CISA in the Known Exploited Vulnerabilities (KEV) catalog. CISA’s KEV entry shows it was added on 2025-05-19 and sets a remediation due date of 2025-06-09. Because it is a known-exploited issue, organizations using BioTime should treat it as a high-priority remediation item and follow vendor guidance or remove the product if mitigations are not available.

Vendor
ZKTeco
Product
BioTime
CVSS
Unknown
CISA KEV
Listed
Original CVE published
2025-05-19
Original CVE updated
2025-05-19
Advisory published
2025-05-19
Advisory updated
2025-05-19

Who should care

Security teams, IT administrators, and asset owners responsible for ZKTeco BioTime deployments should prioritize this advisory, especially environments exposed to external users or connected to sensitive identity/timekeeping data. Incident response and vulnerability management teams should also track it as a known-exploited issue.

Technical summary

The supplied sources identify the issue as a path traversal vulnerability in ZKTeco BioTime. Path traversal flaws can let an attacker influence file or path handling in unintended ways. The provided source corpus does not include affected versions, CVSS data, or a detailed impact statement, so no additional technical claims are made here. The strongest confirmed fact is that CISA has classified this CVE as known exploited.

Defensive priority

High. CISA KEV inclusion indicates confirmed exploitation and a near-term remediation deadline in the supplied timeline. In defensive programs, KEV-listed vulnerabilities generally outrank routine patching work, especially when the affected product is internet-facing or supports privileged operational workflows.

Recommended defensive actions

  • Check whether ZKTeco BioTime is deployed anywhere in the environment, including subsidiaries and managed service estates.
  • Review vendor security bulletins and apply vendor-recommended mitigations as soon as possible.
  • If mitigations are unavailable or cannot be validated, plan to discontinue use of the product in line with CISA guidance.
  • Restrict access to BioTime to trusted networks and administrative users while remediation is underway.
  • Validate that vulnerability and asset inventories are updated so the product cannot be missed in future KEV tracking.
  • Monitor for suspicious access patterns or unexpected file-access behavior associated with the application.

Evidence notes

Evidence is limited to the supplied CISA KEV metadata and official references. CISA’s KEV feed names the vulnerability as a ZKTeco BioTime path traversal issue, marks it as known exploited, and provides the remediation guidance to apply vendor mitigations or discontinue use if mitigations are unavailable. The provided record also links to the official CVE and NVD entries, but the corpus does not include additional version-specific or CVSS details.

Official resources

The supplied timeline shows the KEV entry and CVE record dates as 2025-05-19, with a remediation due date of 2025-06-09 in the KEV metadata. This debrief does not infer the original vulnerability discovery date or publication timing beyond